The fact that DTX3L was overexpressed in prostate cancer patient samples and that DTX3L overexpression inhibited HR and caused chromosomal instability prompted us to explore whether DTX3L overexpression sensitizes prostate cancer cells to synthetic lethality by PARP inhibitors. The gene discussed is DTX3L; the disease is prostate carcinoma.